Momegalen (Mometasone Furoate Ph. Eur.)

Mometasone furoate, the active ingredient in Momegalen, is a glucocorticoid presented as a topical formulation for cutaneous use. It is employed to reduce inflammation and allergic responses in various skin disorders, particularly in patients with psoriasis, atopic dermatitis, contact dermatitis, and seborrheic dermatitis.

GNH USA supplies Momegalen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global market demands. Our distribution network ensures reliable delivery across Europe, Asia, Africa and the Americas.

Momegalen (mometasone furoate) is used to treat inflammatory skin conditions by modulating the local immune response. - Psoriasis: reduces plaque formation and erythema, improving skin appearance. - Atopic dermatitis: alleviates itching and inflammation, helping restore barrier function. - Contact dermatitis: diminishes allergic reactions and redness caused by irritants. - Seborrheic dermatitis: controls scaling and inflammation on scalp and facial areas. - Other inflammatory skin conditions: provides anti‑inflammatory relief in various dermatoses.

Topical application of Momegalen may be associated with local and systemic adverse reactions, although most are mild and reversible.

Common Side Effects: - Skin irritation: mild burning or stinging at the application site. - Pruritus: transient itching after use. - Dryness: localized skin dryness or flaking. - Erythema: mild redness of the treated area. - Folliculitis: inflammation of hair follicles. - Hypertrichosis: increased hair growth in the area.

Serious or Rare Side Effects: - Skin atrophy: thinning of the epidermis with prolonged use. - Telangiectasia: visible small blood vessels on the skin. - Hypersensitivity reactions: rash, urticaria, or angioedema. - Systemic cortisol suppression: adrenal insufficiency with extensive application. - Secondary infection: bacterial, fungal or viral infection of the skin. - Delayed wound healing: impaired recovery of skin injuries.

When prescribing Momegalen, clinicians should consider several safety measures to minimize risks and ensure optimal therapeutic outcomes. - Duration of therapy: limit use to the shortest effective period to reduce skin atrophy. - Application area: avoid large surface areas or occlusive dressings unless directed. - Pediatric use: use with caution in children; monitor for growth suppression. - Concomitant steroids: avoid simultaneous use of other potent corticosteroids on the same site. - Systemic absorption: be aware of potential adrenal suppression with extensive or prolonged use. - Pregnancy and lactation: assess risk‑benefit; use only if clearly needed. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Momegalen can interact with other agents that affect corticosteroid metabolism or skin integrity, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Systemic CYP3A4 inhibitors: may increase systemic exposure when large areas are treated. - Other topical corticosteroids: concurrent use can amplify local and systemic effects. - Antifungal agents (e.g., ketoconazole): can enhance steroid absorption through compromised skin.

Moderate Interactions (Monitor Closely): - Antiviral creams (e.g., acyclovir): may reduce efficacy of antiviral treatment. - Immunosuppressants (e.g., cyclosporine): monitor for additive immunosuppression. - Skin barrier disruptors (e.g., harsh soaps): may increase irritation risk.